• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks 
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks

    Volume
    64
    Pagination
    39A - 40A
    ISSN
    0270-9139
    Metadata
    Show full item record
    Authors
    Foster, GR; Agarwal, K; Cramp, M; Moreea, S; Barclay, ST; Collier, J; Brown, AS; Ryder, SD; Ustianowski, A; Forton, DM
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/19346
    Collections
    • Centre for Immunobiology [927]
    Copyright statements
    Copyright © 2016 American Association for the Study of Liver Diseases.
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.